Inventor · disambiguated record
Sandesh Seth
Also filed as: SETH SANDESH
1 granted patent·18 pending applications·1 citations·filing 2018–2024
17Inventor score
Files withACTINIUM PHARMACEUTICALS INC19
Top patents by PatentIndex Score
19 records- 0171US11912780B2Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2018·Granted Feb 27, 2024·1 cites·25 claims
- 0267US2025121105A1Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0364US2024158528A1Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapiesACTINIUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0458US2025205375A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0556US2025073274A1Methods for treating cd33-positive hematological malignanciesACTINIUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0654US2023248855A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0753US2022251239A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0853US2022288244A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0952US2022211886A1Combination radioimmunotherapy and cd47 blockade in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1051US2024390532A1Radioimmunoconjugates targeting grp78 for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1151US2024216554A1Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1250US2025339571A1Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1349US2024226345A1Radioimmunoconjugates targeting calreticulin for use in the treatment of cancerACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1449US2022143228A1Her3 radioimmunotherapy for the treatment of solid cancersACTINIUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1549US2022072167A1Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody RadioconjugatesACTINIUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1648US2024197931A1Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cellsACTINIUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1742US2022125962A1Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and MethodsACTINIUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1833US2023132400A9Combination therapy for treatment of a hematological diseaseACTINIUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1932US2020121815A1Treatments for a hematological malignancyACTINIUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sandesh Seth files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →